GMP IPO
📋 Filings Intelligence
About Contact
LIVE - Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement - financial results, order wins, dividends, mergers and more. Updated live.

-
Filed today
-
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings -

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Ind-Swift Laboratories Ltd

Ind-Swift Labs: Rs. 137.20 crore preferential issue utilization reported

FUNDRAISE ▲ Positive Development LOW RISK
📅 Filed on BSE: 03 Nov 2026, 02:56 PM IST  ·  BSE ID: fb7a67ba-db7e-4e21-adc1-28b9add31e87
View Original BSE Filing (PDF)
💡
In Simple Terms
The company confirmed how money from a recent share sale was used, with no changes to the original plan.
🤖 AI Summary
  • Ind-Swift Laboratories submitted its Q2 FY27 Monitoring Agency Report for preferential issue funds.
  • Report covers utilization of funds from 70,00,000 fully convertible warrants.
  • Total funds raised through the preferential issue aggregated to Rs. 137.20 crore.
  • No deviation from the stated objects of the issue was reported by the monitoring agency.
🔢 Key Numbers - exact figures from BSE filing, not rounded
Funds raised through preferential issue
Rs. 137.20 crore
Fully Convertible Warrants issued
70,00,000
Quarter ended
September 30, 2026
🏢 How This Affects the Company
📈
Business Impact
Confirms adherence to stated fundraising objectives, maintaining transparency with investors regarding fund deployment.
💰
Financial Impact
Reinforces the financial commitment to the planned use of Rs. 137.20 crore raised via preferential issue.
⚠️
Risk Impact
Mitigates potential risk associated with misallocation of funds, as confirmed by the monitoring agency.
👥 What This Means For Shareholders
✅
Action Required
No action is required from shareholders regarding this filing.
👤
Who Is Affected
All shareholders are affected by the company's adherence to its stated financial plans.
🔍
Management Signal
This signals management's commitment to transparency and adherence to the stated objectives of the preferential issue.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List - track these upcoming events
Next Monitoring Agency Report for Q3 FY27.
Company filings detailing the specific use of funds.
Future preferential issue announcements or related corporate actions.
LOW RISK Standard monitoring agency report confirming fund utilization as per stated objects.
💡 Investor Takeaway
Ind-Swift Laboratories reported no deviation in the utilization of Rs. 137.20 crore raised via preferential issue for the quarter ended September 30, 2026.
⚖️ Strengths & Concerns

✅ Positives

  • Rs. 137.20 crore preferential issue funds utilized as per stated objects, confirmed by monitoring agency.
  • The company has reported no deviation from the objects of its preferential issue for Q2 FY27.
📅 Company Track Record
Ind-Swift Laboratories previously announced a board meeting to consider fundraise on July 10, 2026, and has also made allotments related to ESOPs.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What is Ind-Swift Laboratories' Monitoring Agency Report for Q2 FY27 about?
The report confirms the utilization of funds raised through a preferential issue of 70,00,000 fully convertible warrants, amounting to Rs. 137.20 crore.
Were there any deviations in the utilization of funds for Ind-Swift Laboratories' preferential issue?
No, Ind-Swift Laboratories reported no deviation from the objects of the preferential issue for the quarter ended September 30, 2026.
What was the total amount raised by Ind-Swift Laboratories through its preferential issue?
The preferential issue of 70,00,000 fully convertible warrants aggregated to Rs. 137.20 crore.
Who is the monitoring agency for Ind-Swift Laboratories' preferential issue?
CARE Ratings Limited is the monitoring agency for Ind-Swift Laboratories' preferential issue.

Questions based on this BSE filing only. For information purposes.

You've read one filing

There are 32,000 more, and one of them is about a company you own

Follow a company and we'll email you the moment it files again - explained, not just forwarded. Free.

  • Follow companies and get filings by email
  • Save any filing to read later
  • Two full AI analyses every month, free

No card needed. Sign in with Google in two taps.

⚠️ For Information Only - Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector - takes 5 seconds.